Open-Label, Phase 1 Study of LOR-253 HCl in Patients With Advanced or Metastatic Solid Tumours.

Trial Profile

Open-Label, Phase 1 Study of LOR-253 HCl in Patients With Advanced or Metastatic Solid Tumours.

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Oct 2015

At a glance

  • Drugs APTO 253 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; Biomarker
  • Sponsors Lorus Therapeutics
  • Most Recent Events

    • 24 Feb 2014 Status changed from recruiting to completed, as per ClinicalTrials.gov record.
    • 01 Oct 2013 Results have been presented at the 2013 European Cancer Congress annual meeting according to a Lorus Therapeutics media release. Results were also summarised in the media release.
    • 09 Jul 2013 Promising results reported in a Lorus Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top